SIGLEC15 (NC-318 Biosimilar) Recombinant Monoclonal Antibody

Code CSB-RA761623MB1HU
Size US$9799
Order now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
Alternative Names
5G-12 research-grade biosimilar; NC 318 research-grade biosimilar ;SIGLEC15 antibody; CD33L3 antibody; Sialic acid-binding Ig-like lectin 15 antibody; Siglec-15 antibody; CD33 antigen-like 3 antibody
Species Reactivity
Human
Immunogen
Recombinant Human SIGLEC15 protein
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Clonality
Monoclonal
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
0.01M PBS,pH7.4
Form
Liquid
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Notes
Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity > 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method.
Lead Time
3-4 weeks
Description

This recombinant monoclonal antibody is designed as a research-grade biosimilar to NC-318, targeting SIGLEC15 (Sialic Acid Binding Ig-like Lectin 15), a transmembrane protein that plays critical roles in immune regulation and bone remodeling. SIGLEC15 functions as an immune checkpoint molecule expressed on tumor-associated macrophages and myeloid cells, where it suppresses T cell activation and promotes an immunosuppressive tumor microenvironment. This target has emerged as particularly relevant in oncology research, as SIGLEC15 expression is largely absent in normal tissues but upregulated in various solid tumors, including non-small cell lung cancer, colorectal cancer, and head and neck cancers, making it an attractive therapeutic target distinct from PD-1/PD-L1 pathways.

NC-318 represents a pioneering anti-SIGLEC15 antibody that entered clinical development as a potential cancer immunotherapy agent. This biosimilar antibody provides researchers with a valuable tool for investigating SIGLEC15-mediated immune suppression, exploring combination immunotherapy strategies, and studying macrophage polarization in the tumor microenvironment. It supports investigations into novel immune checkpoint mechanisms and osteoclast biology.

Usage
It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Binds sialylated glycoproteins.
Gene References into Functions
  1. Siglec-15 recognizes the tumoral sTn antigen and transduces a signal for enhanced TGF-beta secretion in TAMs PMID: 23035012
Subcellular Location
Membrane; Single-pass type I membrane protein.
Protein Families
Immunoglobulin superfamily, SIGLEC (sialic acid binding Ig-like lectin) family
Tissue Specificity
Expressed in macrophage and/or dendritic cells of spleen and lymph nodes.
Database Links

HGNC: 27596

KEGG: hsa:284266

STRING: 9606.ENSP00000374125

UniGene: Hs.287692

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2026 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*